Glucotrack, Inc.
No SEC Form 4 filings for $GCTK in the last 30 days.
See all $GCTK insider activity →Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001506983 0001506983 2026-08-07 2026-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
Glucotrack, Inc. (GCTK) filed an 8-K saying that on Aug. 4, 2026 it arranged follow-on financing totaling $5.5M through a $3.5M bridge follow-on and an interim PIPE. The bridge follow-on issued $3.5M senior secured convertible notes at 8% interest, with 22% OID, plus warrants, subject to stockholder approval for conversion and exercise.
Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of August 4, 2026, between Glucotrack, Inc., a Delaware corporation (the “ Company ”), and the purchaser identified on the signature page he
Over the past 7 days, alphai's AI scored 1 news story mentioning GCTK (Glucotrack, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent GCTK coverage spans corporate actions, market movers and technology.
The amendment increases near-term equity issuance mechanics tied to a minimum price and adds a potential $1.0M true-up if the commitment fee price falls below the minimum.
Financing terms imply near-term dilution risk and potential volatility around the required Nasdaq stockholder approval.
The filing signals a capital raise or financing transaction via a securities purchase agreement, likely involving warrants and new debt-like obligations.
GlucoTrack, Inc. said it has a definitive agreement for a private placement with institutional investors. It plans to issue 2,666,666 units at $0.75 each, including one share and one five-year warrant priced at $1.50. The company expects total gross proceeds of about $5.5 million from equity and convertible debt.
Glucotrack Inc. said it raised about $5.5 million through institutional financing, including a $2.0 million equity investment priced at $0.75 per unit (share plus 5-year warrant at $1.50) and $3.5 million in follow-on convertible debt. The company plans to use proceeds to fund its implantable continuous blood glucose monitoring program and biopharmaceutical platform via Lōkahi Therapeutics.
alphai scores every news story that mentions GCTK with an AI model for sentiment and relevance, and aggregates insider trades from Glucotrack, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001506983 0001506983 2026-08-07 2026-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readGlucotrack, Inc. (GCTK) filed an 8-K saying that on Aug. 4, 2026 it arranged follow-on financing totaling $5.5M through a $3.5M bridge follow-on and an interim PIPE. The bridge follow-on issued $3.5M senior secured convertible notes at 8% interest, with 22% OID, plus warrants, subject to stockholder approval for conversion and exercise.
4 min readGlucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of August 4, 2026, between Glucotrack, Inc., a Delaware corporation (the “ Company ”), and the purchaser identified on the signature page he
4 min readGlucoTrack, Inc. said it has a definitive agreement for a private placement with institutional investors. It plans to issue 2,666,666 units at $0.75 each, including one share and one five-year warrant priced at $1.50. The company expects total gross proceeds of about $5.5 million from equity and convertible debt.
2 min readGlucotrack Inc. said it raised about $5.5 million through institutional financing, including a $2.0 million equity investment priced at $0.75 per unit (share plus 5-year warrant at $1.50) and $3.5 million in follow-on convertible debt. The company plans to use proceeds to fund its implantable continuous blood glucose monitoring program and biopharmaceutical platform via Lōkahi Therapeutics.
4 min readToday's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.
6 min readGlucoTrack (NASDAQ:GCTK) shares rose more than 70% after hours after the company said nonclinical minipig data support its LT-100 program using one subcutaneous injection per visit for knee osteoarthritis pain, replacing up to 15 intradermal injections. The update follows an FDA Type C meeting in May 2026, with clinical evaluation starting as early as Q4 2026 and readout in H1 2027.
5 min readGlucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001506983 0001506983 2026-07-22 2026-07-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readHealthcare stocks moved on multiple FDA and EU updates. Novartis (NVS) won FDA approval for Fabhalta in IgA nephropathy; Merck (MRK) got FDA nod for LIPFENDRA and KEYTRUDA+Padcev in bladder cancer; Novo Nordisk (NVO) received EU approval for oral Wegovy. Lilly (LLY) agreed to buy AtaiBeckley for $6.75/share plus up to $2.50 CVR.
7 min readGlucotrack, Inc. (NASDAQ: GCTK) and its operating business Lokahi Therapeutics completed a bridge financing to fund strategic growth, including advancing the combined Glucotrack-Lokahi platform and other planned capital markets activities. The financing follows Glucotrack’s recent business combination with Lokahi. E.F. Hutton & Co. acted as exclusive advisor and placement agent.
2 min read
